Quest Diagnostics (DGX) EBIT (2009 - 2025)

Quest Diagnostics has disclosed EBIT across 17 years of filings, most recently posting $1.6 billion for FY2025.

• EBIT for Q1 2026 came in at $399.0 million, up 15.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 15.59% YoY), and the FY2025 annual result was $1.6 billion, up 15.6% from the prior year.
• EBIT came in at $1.6 billion for FY2025 at Quest Diagnostics, up from $1.3 billion in the prior year.
• In the past five years, EBIT ranged from a high of $2.4 billion in FY2021 to a low of $1.3 billion in FY2023.
• The 5-year median for EBIT is $1.4 billion (2022), against an average of $1.6 billion.
• Across the five-year window, EBIT climbed 20.8% in 2021 and plunged 40.03% in 2022, its largest moves.
• Quest Diagnostics' EBIT stood at $2.4 billion in 2021, then slumped by 40.03% to $1.4 billion in 2022, then decreased by 11.62% to $1.3 billion in 2023, then gained by 6.66% to $1.3 billion in 2024, then climbed by 15.6% to $1.6 billion in 2025.
• The last three EBIT figures came in at $1.6 billion (FY2025), $1.3 billion (FY2024), and $1.3 billion (FY2023), per Business Quant data.